Janus Henderson Group PLC Buys New Position in NeoGenomics, Inc. (NEO)

Janus Henderson Group PLC bought a new stake in NeoGenomics, Inc. (NASDAQ:NEO) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 2,304,767 shares of the medical research company’s stock, valued at approximately $20,651,000. Janus Henderson Group PLC owned 2.90% of NeoGenomics as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Royce & Associates LP lifted its stake in shares of NeoGenomics by 57.5% in the 2nd quarter. Royce & Associates LP now owns 955,900 shares of the medical research company’s stock valued at $8,565,000 after purchasing an additional 348,900 shares during the period. Blair William & Co. IL lifted its stake in shares of NeoGenomics by 8.1% in the 2nd quarter. Blair William & Co. IL now owns 377,672 shares of the medical research company’s stock valued at $3,384,000 after purchasing an additional 28,213 shares during the period. Cadence Capital Management LLC lifted its stake in shares of NeoGenomics by 5.8% in the 2nd quarter. Cadence Capital Management LLC now owns 150,419 shares of the medical research company’s stock valued at $1,348,000 after purchasing an additional 8,241 shares during the period. Falcon Point Capital LLC lifted its stake in shares of NeoGenomics by 338.6% in the 2nd quarter. Falcon Point Capital LLC now owns 1,100,474 shares of the medical research company’s stock valued at $9,860,000 after purchasing an additional 849,589 shares during the period. Finally, Suffolk Capital Management LLC lifted its stake in shares of NeoGenomics by 12.2% in the 2nd quarter. Suffolk Capital Management LLC now owns 199,569 shares of the medical research company’s stock valued at $1,788,000 after purchasing an additional 21,621 shares during the period. Institutional investors own 80.41% of the company’s stock.

In other NeoGenomics news, Director Alison L. Hannah acquired 20,000 shares of the firm’s stock in a transaction dated Thursday, July 27th. The stock was purchased at an average price of $9.19 per share, for a total transaction of $183,800.00. Following the acquisition, the director now owns 38,782 shares in the company, valued at approximately $356,406.58. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 11.20% of the company’s stock.

NeoGenomics, Inc. (NASDAQ:NEO) opened at 9.07 on Thursday. The company’s 50-day moving average price is $10.62 and its 200-day moving average price is $8.99. NeoGenomics, Inc. has a 52-week low of $6.90 and a 52-week high of $11.63. The company’s market cap is $720.05 million.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.01 by $0.03. NeoGenomics had a positive return on equity of 6.09% and a negative net margin of 2.81%. The firm had revenue of $66.09 million during the quarter, compared to analyst estimates of $62.95 million. During the same quarter in the prior year, the business posted $0.04 EPS. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. Equities research analysts expect that NeoGenomics, Inc. will post $0.16 EPS for the current fiscal year.

A number of research analysts recently weighed in on NEO shares. Gabelli started coverage on NeoGenomics in a research report on Thursday, August 24th. They set a “buy” rating and a $9.00 price objective for the company. BidaskClub raised NeoGenomics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 19th. Zacks Investment Research raised NeoGenomics from a “sell” rating to a “hold” rating in a research report on Saturday, July 29th. BTIG Research lowered NeoGenomics from a “buy” rating to a “neutral” rating in a research report on Monday, September 11th. Finally, ValuEngine raised NeoGenomics from a “sell” rating to a “hold” rating in a research report on Monday, August 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $10.33.

WARNING: This story was first posted by The Led

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Royce & Associates LP lifted its stake in shares of NeoGenomics by 57.5% in the 2nd quarter. Royce & Associates LP now owns 955,900 shares of the medical research company’s stock valued at $8,565,000 after purchasing an additional 348,900 shares during the period. Blair William & Co. IL lifted its stake in shares of NeoGenomics by 8.1% in the 2nd quarter. Blair William & Co. IL now owns 377,672 shares of the medical research company’s stock valued at $3,384,000 after purchasing an additional 28,213 shares during the period. Cadence Capital Management LLC lifted its stake in shares of NeoGenomics by 5.8% in the 2nd quarter. Cadence Capital Management LLC now owns 150,419 shares of the medical research company’s stock valued at $1,348,000 after purchasing an additional 8,241 shares during the period. Falcon Point Capital LLC lifted its stake in shares of NeoGenomics by 338.6% in the 2nd quarter. Falcon Point Capital LLC now owns 1,100,474 shares of the medical research company’s stock valued at $9,860,000 after purchasing an additional 849,589 shares during the period. Finally, Suffolk Capital Management LLC lifted its stake in shares of NeoGenomics by 12.2% in the 2nd quarter. Suffolk Capital Management LLC now owns 199,569 shares of the medical research company’s stock valued at $1,788,000 after purchasing an additional 21,621 shares during the period. Institutional investors own 80.41% of the company’s stock.

In other NeoGenomics news, Director Alison L. Hannah acquired 20,000 shares of the firm’s stock in a transaction dated Thursday, July 27th. The stock was purchased at an average price of $9.19 per share, for a total transaction of $183,800.00. Following the acquisition, the director now owns 38,782 shares in the company, valued at approximately $356,406.58. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 11.20% of the company’s stock.

NeoGenomics, Inc. (NASDAQ:NEO) opened at 9.07 on Thursday. The company’s 50-day moving average price is $10.62 and its 200-day moving average price is $8.99. NeoGenomics, Inc. has a 52-week low of $6.90 and a 52-week high of $11.63. The company’s market cap is $720.05 million.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.01 by $0.03. NeoGenomics had a positive return on equity of 6.09% and a negative net margin of 2.81%. The firm had revenue of $66.09 million during the quarter, compared to analyst estimates of $62.95 million. During the same quarter in the prior year, the business posted $0.04 EPS. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. Equities research analysts expect that NeoGenomics, Inc. will post $0.16 EPS for the current fiscal year.

A number of research analysts recently weighed in on NEO shares. Gabelli started coverage on NeoGenomics in a research report on Thursday, August 24th. They set a “buy” rating and a $9.00 price objective for the company. BidaskClub raised NeoGenomics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 19th. Zacks Investment Research raised NeoGenomics from a “sell” rating to a “hold” rating in a research report on Saturday, July 29th. BTIG Research lowered NeoGenomics from a “buy” rating to a “neutral” rating in a research report on Monday, September 11th. Finally, ValuEngine raised NeoGenomics from a “sell” rating to a “hold” rating in a research report on Monday, August 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $10.33.

WARNING: This story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://ledgergazette.com/2017/10/19/janus-henderson-group-plc-buys-new-position-in-neogenomics-inc-neo.html.

NeoGenomics Company Profile

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply